GeneDx Holdings Corp. (NASDAQ: WGS) Stock Competitors & Peer Comparison
See WGS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for WGS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| WGS | $73.09 | +3.00% | 2.2B | 203.03 | $0.36 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.71% |
| TMO | $654.80 | +0.35% | 242.2B | 28.28 | $23.16 | +0.28% |
| DHR | $214.06 | +1.09% | 150.5B | 26.82 | $7.98 | +0.71% |
| NTRA | $410.35 | +0.46% | 58.8B | -310.87 | -$1.32 | N/A |
| A | $167.78 | +0.66% | 47.4B | 28.86 | $5.81 | +0.60% |
| IQV | $258.21 | -0.96% | 42.5B | 21.29 | $12.13 | N/A |
| WAT | $425.21 | -0.08% | 41.7B | 31.08 | $13.68 | N/A |
| ILMN | $273.04 | +2.75% | 41.3B | 54.28 | $5.03 | N/A |
| IDXX | $518.39 | +0.12% | 40.9B | 36.45 | $14.22 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
WGS vs DHR-PB Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, WGS's ROE is -0.39%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, WGS is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for WGS.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
WGS vs TMO Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, TMO has a market cap of 242.2B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while TMO trades at $654.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas TMO's P/E ratio is 28.28. In terms of profitability, WGS's ROE is -0.39%, compared to TMO's ROE of +0.13%. Regarding short-term risk, WGS is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for WGS.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
WGS vs DHR Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, DHR has a market cap of 150.5B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while DHR trades at $214.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas DHR's P/E ratio is 26.82. In terms of profitability, WGS's ROE is -0.39%, compared to DHR's ROE of +0.08%. Regarding short-term risk, WGS is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for WGS.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
WGS vs NTRA Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, NTRA has a market cap of 58.8B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while NTRA trades at $410.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas NTRA's P/E ratio is -310.87. In terms of profitability, WGS's ROE is -0.39%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, WGS is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for WGS.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
WGS vs A Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, A has a market cap of 47.4B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while A trades at $167.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas A's P/E ratio is 28.86. In terms of profitability, WGS's ROE is -0.39%, compared to A's ROE of +0.20%. Regarding short-term risk, WGS is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for WGS.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
WGS vs IQV Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, IQV has a market cap of 42.5B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while IQV trades at $258.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas IQV's P/E ratio is 21.29. In terms of profitability, WGS's ROE is -0.39%, compared to IQV's ROE of +0.22%. Regarding short-term risk, WGS is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for WGS.Check IQV's competition here
Waters Corporation (NYSE: WAT)
WGS vs WAT Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, WAT has a market cap of 41.7B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while WAT trades at $425.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas WAT's P/E ratio is 31.08. In terms of profitability, WGS's ROE is -0.39%, compared to WAT's ROE of +0.02%. Regarding short-term risk, WGS is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for WGS.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
WGS vs ILMN Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, ILMN has a market cap of 41.3B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while ILMN trades at $273.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas ILMN's P/E ratio is 54.28. In terms of profitability, WGS's ROE is -0.39%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, WGS is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for WGS.Check ILMN's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
WGS vs IDXX Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, IDXX has a market cap of 40.9B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while IDXX trades at $518.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas IDXX's P/E ratio is 36.45. In terms of profitability, WGS's ROE is -0.39%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, WGS is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for WGS.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
WGS vs MTD Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, MTD has a market cap of 30B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while MTD trades at $1,486.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas MTD's P/E ratio is 34.17. In terms of profitability, WGS's ROE is -0.39%, compared to MTD's ROE of -12.00%. Regarding short-term risk, WGS is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for WGS.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
WGS vs DGX Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, DGX has a market cap of 25.7B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while DGX trades at $233.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas DGX's P/E ratio is 23.00. In terms of profitability, WGS's ROE is -0.39%, compared to DGX's ROE of +0.14%. Regarding short-term risk, WGS is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for WGS.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
WGS vs LH Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, LH has a market cap of 25.3B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while LH trades at $308.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas LH's P/E ratio is 18.31. In terms of profitability, WGS's ROE is -0.39%, compared to LH's ROE of +0.12%. Regarding short-term risk, WGS is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for WGS.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
WGS vs GH Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, GH has a market cap of 23.9B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while GH trades at $177.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas GH's P/E ratio is -50.95. In terms of profitability, WGS's ROE is -0.39%, compared to GH's ROE of +2.11%. Regarding short-term risk, WGS is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for WGS.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
WGS vs EXAS Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas EXAS's P/E ratio is -95.37. In terms of profitability, WGS's ROE is -0.39%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, WGS is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for WGS.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
WGS vs ILMNV Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas ILMNV's P/E ratio is N/A. In terms of profitability, WGS's ROE is -0.39%, compared to ILMNV's ROE of N/A. Regarding short-term risk, WGS is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for WGS.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
WGS vs RVTY Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, RVTY has a market cap of 16.9B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while RVTY trades at $151.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas RVTY's P/E ratio is 28.30. In terms of profitability, WGS's ROE is -0.39%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, WGS is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for WGS.Check RVTY's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
WGS vs MEDP Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, MEDP has a market cap of 16.7B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while MEDP trades at $599.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas MEDP's P/E ratio is 35.14. In terms of profitability, WGS's ROE is -0.39%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, WGS is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for WGS.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
WGS vs PKI Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas PKI's P/E ratio is 41.45. In terms of profitability, WGS's ROE is -0.39%, compared to PKI's ROE of +0.03%. Regarding short-term risk, WGS is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for WGS.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
WGS vs CRL Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, CRL has a market cap of 14B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while CRL trades at $290.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas CRL's P/E ratio is 29.31. In terms of profitability, WGS's ROE is -0.39%, compared to CRL's ROE of -0.08%. Regarding short-term risk, WGS is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for WGS.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
WGS vs ICLR Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, ICLR has a market cap of 12.4B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while ICLR trades at $162.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas ICLR's P/E ratio is 13.22. In terms of profitability, WGS's ROE is -0.39%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, WGS is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for WGS.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
WGS vs QGEN Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, QGEN has a market cap of 9.2B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while QGEN trades at $44.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas QGEN's P/E ratio is 18.49. In terms of profitability, WGS's ROE is -0.39%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, WGS is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for WGS.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
WGS vs GRAL Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, GRAL has a market cap of 5.7B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while GRAL trades at $143.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas GRAL's P/E ratio is -13.60. In terms of profitability, WGS's ROE is -0.39%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, WGS is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for WGS.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
WGS vs RDNT Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while RDNT trades at $69.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas RDNT's P/E ratio is 152.02. In terms of profitability, WGS's ROE is -0.39%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, WGS is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for WGS.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
WGS vs SHC Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while SHC trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas SHC's P/E ratio is 18.98. In terms of profitability, WGS's ROE is -0.39%, compared to SHC's ROE of +0.27%. Regarding short-term risk, WGS is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for WGS.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
WGS vs BLLN Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, BLLN has a market cap of 4.9B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while BLLN trades at $105.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas BLLN's P/E ratio is 151.29. In terms of profitability, WGS's ROE is -0.39%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, WGS is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for WGS.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
WGS vs SYNH Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas SYNH's P/E ratio is 61.40. In terms of profitability, WGS's ROE is -0.39%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, WGS is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for WGS.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
WGS vs VCYT Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while VCYT trades at $45.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas VCYT's P/E ratio is 22.91. In terms of profitability, WGS's ROE is -0.39%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, WGS is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for WGS.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
WGS vs CDNA Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, CDNA has a market cap of 3.5B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while CDNA trades at $67.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas CDNA's P/E ratio is 79.94. In terms of profitability, WGS's ROE is -0.39%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, WGS is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for WGS.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
WGS vs OLK Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas OLK's P/E ratio is -96.59. In terms of profitability, WGS's ROE is -0.39%, compared to OLK's ROE of -0.07%. Regarding short-term risk, WGS is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for WGS.Check OLK's competition here
Personalis, Inc. (NASDAQ: PSNL)
WGS vs PSNL Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while PSNL trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas PSNL's P/E ratio is -14.94. In terms of profitability, WGS's ROE is -0.39%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, WGS is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for WGS.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
WGS vs OPK Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while OPK trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas OPK's P/E ratio is -5.78. In terms of profitability, WGS's ROE is -0.39%, compared to OPK's ROE of -0.06%. Regarding short-term risk, WGS is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for WGS.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
WGS vs CSTL Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while CSTL trades at $35.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas CSTL's P/E ratio is -53.88. In terms of profitability, WGS's ROE is -0.39%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, WGS is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for WGS.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
WGS vs FLGT Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, FLGT has a market cap of 610M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while FLGT trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas FLGT's P/E ratio is 2148.00. In terms of profitability, WGS's ROE is -0.39%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, WGS is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for WGS.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
WGS vs GRALV Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas GRALV's P/E ratio is N/A. In terms of profitability, WGS's ROE is -0.39%, compared to GRALV's ROE of N/A. Regarding short-term risk, WGS is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for WGS.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
WGS vs NEO Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, NEO has a market cap of 474.6M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while NEO trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas NEO's P/E ratio is 142.08. In terms of profitability, WGS's ROE is -0.39%, compared to NEO's ROE of -0.06%. Regarding short-term risk, WGS is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for WGS.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
WGS vs MYGN Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, MYGN has a market cap of 428.8M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while MYGN trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas MYGN's P/E ratio is -34.92. In terms of profitability, WGS's ROE is -0.39%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, WGS is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for WGS.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
WGS vs CO Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas CO's P/E ratio is 5.06. In terms of profitability, WGS's ROE is -0.39%, compared to CO's ROE of +0.11%. Regarding short-term risk, WGS is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for WGS.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
WGS vs FLDM Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas FLDM's P/E ratio is -4.74. In terms of profitability, WGS's ROE is -0.39%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, WGS is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for WGS.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
WGS vs BDSX Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, BDSX has a market cap of 225.6M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while BDSX trades at $27.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas BDSX's P/E ratio is -8.74. In terms of profitability, WGS's ROE is -0.39%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, WGS is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for WGS.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
WGS vs XGN Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, XGN has a market cap of 197.4M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while XGN trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas XGN's P/E ratio is -10.09. In terms of profitability, WGS's ROE is -0.39%, compared to XGN's ROE of -1.22%. Regarding short-term risk, WGS is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for WGS.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
WGS vs FRNM Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, FRNM has a market cap of 133.1M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while FRNM trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas FRNM's P/E ratio is N/A. In terms of profitability, WGS's ROE is -0.39%, compared to FRNM's ROE of N/A. Regarding short-term risk, WGS is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for WGS.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
WGS vs GTH Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas GTH's P/E ratio is -1.11. In terms of profitability, WGS's ROE is -0.39%, compared to GTH's ROE of -1.01%. Regarding short-term risk, WGS is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for WGS.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
WGS vs GENE Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas GENE's P/E ratio is -38.25. In terms of profitability, WGS's ROE is -0.39%, compared to GENE's ROE of -1.85%. Regarding short-term risk, WGS is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for WGS.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
WGS vs IMDX Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, IMDX has a market cap of 111.1M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while IMDX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas IMDX's P/E ratio is -2.31. In terms of profitability, WGS's ROE is -0.39%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, WGS is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for WGS.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
WGS vs SERA Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, SERA has a market cap of 79.1M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while SERA trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas SERA's P/E ratio is -3.18. In terms of profitability, WGS's ROE is -0.39%, compared to SERA's ROE of -0.47%. Regarding short-term risk, WGS is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for WGS.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
WGS vs PRPO Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, PRPO has a market cap of 41.3M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while PRPO trades at $23.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas PRPO's P/E ratio is -35.58. In terms of profitability, WGS's ROE is -0.39%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, WGS is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for WGS.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
WGS vs QUCY Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while QUCY trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas QUCY's P/E ratio is -0.06. In terms of profitability, WGS's ROE is -0.39%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, WGS is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for WGS.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
WGS vs MDXH Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, MDXH has a market cap of 29.3M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas MDXH's P/E ratio is -0.78. In terms of profitability, WGS's ROE is -0.39%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, WGS is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for WGS.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
WGS vs AKU Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas AKU's P/E ratio is -0.13. In terms of profitability, WGS's ROE is -0.39%, compared to AKU's ROE of -5.32%. Regarding short-term risk, WGS is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for WGS.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
WGS vs BNR Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, BNR has a market cap of 17.3M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while BNR trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas BNR's P/E ratio is -18.84. In terms of profitability, WGS's ROE is -0.39%, compared to BNR's ROE of -0.13%. Regarding short-term risk, WGS is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for WGS.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
WGS vs CEMI Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas CEMI's P/E ratio is -0.63. In terms of profitability, WGS's ROE is -0.39%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, WGS is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for WGS.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
WGS vs ENZ Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas ENZ's P/E ratio is -2.24. In terms of profitability, WGS's ROE is -0.39%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, WGS is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for WGS.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
WGS vs PMD Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas PMD's P/E ratio is -5.24. In terms of profitability, WGS's ROE is -0.39%, compared to PMD's ROE of -0.32%. Regarding short-term risk, WGS is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for WGS.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
WGS vs ME Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas ME's P/E ratio is -0.03. In terms of profitability, WGS's ROE is -0.39%, compared to ME's ROE of -42.03%. Regarding short-term risk, WGS is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for WGS.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
WGS vs MYNZ Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, WGS's ROE is -0.39%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, WGS is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for WGS.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
WGS vs BIAFW Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, BIAFW has a market cap of 11.8M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while BIAFW trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas BIAFW's P/E ratio is 1.25. In terms of profitability, WGS's ROE is -0.39%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, WGS is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for WGS.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
WGS vs CHEK Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas CHEK's P/E ratio is -0.43. In terms of profitability, WGS's ROE is -0.39%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, WGS is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for WGS.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
WGS vs CNTG Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas CNTG's P/E ratio is -0.23. In terms of profitability, WGS's ROE is -0.39%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, WGS is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for WGS.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
WGS vs ADVB Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, ADVB has a market cap of 9.3M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while ADVB trades at $6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas ADVB's P/E ratio is -61.00. In terms of profitability, WGS's ROE is -0.39%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, WGS is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for WGS.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
WGS vs NDRA Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while NDRA trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas NDRA's P/E ratio is -0.90. In terms of profitability, WGS's ROE is -0.39%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, WGS is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for WGS.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
WGS vs APDN Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas APDN's P/E ratio is -0.10. In terms of profitability, WGS's ROE is -0.39%, compared to APDN's ROE of -7.23%. Regarding short-term risk, WGS is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for WGS.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
WGS vs NVTA Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas NVTA's P/E ratio is -0.00. In terms of profitability, WGS's ROE is -0.39%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, WGS is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for WGS.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
WGS vs LMDXW Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, WGS's ROE is -0.39%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, WGS is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for WGS.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
WGS vs LMDX Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas LMDX's P/E ratio is -0.01. In terms of profitability, WGS's ROE is -0.39%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, WGS is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for WGS.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
WGS vs DMTK Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas DMTK's P/E ratio is -0.04. In terms of profitability, WGS's ROE is -0.39%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, WGS is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for WGS.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
WGS vs NOTV Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas NOTV's P/E ratio is -0.03. In terms of profitability, WGS's ROE is -0.39%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, WGS is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for WGS.Check NOTV's competition here
iSpecimen Inc. (NASDAQ: ISPC)
WGS vs ISPC Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, ISPC has a market cap of 2.6M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while ISPC trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas ISPC's P/E ratio is -0.03. In terms of profitability, WGS's ROE is -0.39%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, WGS is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for WGS.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
WGS vs BIAF Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while BIAF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas BIAF's P/E ratio is -0.71. In terms of profitability, WGS's ROE is -0.39%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, WGS is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for WGS.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
WGS vs SQL Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas SQL's P/E ratio is -0.40. In terms of profitability, WGS's ROE is -0.39%, compared to SQL's ROE of -30.46%. Regarding short-term risk, WGS is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for WGS.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
WGS vs AWH Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas AWH's P/E ratio is -0.09. In terms of profitability, WGS's ROE is -0.39%, compared to AWH's ROE of +1.62%. Regarding short-term risk, WGS is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for WGS.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
WGS vs HTGM Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas HTGM's P/E ratio is -0.03. In terms of profitability, WGS's ROE is -0.39%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, WGS is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for WGS.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
WGS vs BIOC Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas BIOC's P/E ratio is -0.01. In terms of profitability, WGS's ROE is -0.39%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, WGS is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for WGS.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
WGS vs SQLLW Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, WGS's ROE is -0.39%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, WGS is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for WGS.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
WGS vs WGSWW Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, WGS's ROE is -0.39%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, WGS is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for WGS.Check WGSWW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
WGS vs BNGOW Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas BNGOW's P/E ratio is N/A. In terms of profitability, WGS's ROE is -0.39%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, WGS is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for WGS.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
WGS vs CHEKZ Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, WGS's ROE is -0.39%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, WGS is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for WGS.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
WGS vs MEUSW Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas MEUSW's P/E ratio is N/A. In terms of profitability, WGS's ROE is -0.39%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, WGS is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for WGS.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
WGS vs NDRAW Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas NDRAW's P/E ratio is N/A. In terms of profitability, WGS's ROE is -0.39%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, WGS is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for WGS.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
WGS vs PRXL Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas PRXL's P/E ratio is 42.97. In terms of profitability, WGS's ROE is -0.39%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, WGS is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for WGS.Check PRXL's competition here
Danaher Corporation (NYSE: DHR-PA)
WGS vs DHR-PA Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, WGS's ROE is -0.39%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, WGS is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for WGS.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
WGS vs OCDX Comparison October 2026
GeneDx Holdings Corp. (NASDAQ: WGS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WGS stands at 2.2B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, WGS is priced at $73.09 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WGS currently has a P/E ratio of 203.03, whereas OCDX's P/E ratio is -42.28. In terms of profitability, WGS's ROE is -0.39%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, WGS is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for WGS.Check OCDX's competition here